
Patients in England with a form of breast cancer will be offered a new treatment after it was given the green light for NHS use.
The Institute of Cancer Research, London, (ICR) – which worked on the development of the treatment – said olaparib will offer the chance of “longer, healthier lives” for thousands of patients with a certain type of secondary breast cancer.